AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint

Stock Information for AVEO Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AVEO Pharmaceuticals Inc.

LG Chem Completes Acquisition of AVEO Oncology
AVEO Oncology Stockholders Approve Acquisition by LG Chem
AVEO Oncology Reminds Stockholders to Vote "FOR" All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OFIX, AAWW, AVEO, MYOV
Lifshitz Law PLLC Announces Investigations of RBA, AKUS, AVEO, and CLR
AVEO Oncology Reports Third Quarter 2022 Financial Results
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BNFT, ATCO, ABMD, AVEO
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVEO, PEBO, LMST, MYOV

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.